Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of abexinostat at different doses to find out
if it can work with ibrutinib to stop the cancer from growing.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Janssen Scientific Affairs, LLC Xynomic Pharmaceuticals, Inc.